Results 231 to 240 of about 103,961 (275)

Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study. [PDF]

Immunother Adv
Kennedy OJ, Lee R, Blackhall F, Choudhury A, Metcalf R, Waddell T, Lorigan P.   +6 more
europepmc   +1 more source

Immune‐Related Polyradiculoneuropathy Associated With Immune Checkpoint Inhibitors: A Comprehensive Case Series

Brain and Behavior, Volume 16, Issue 5, May 2026.
ABSTRACT Objective Immune‐related polyradiculoneuropathy (irPRN) is a rare but potentially severe neurological adverse event secondary to immune checkpoint inhibitors (ICIs), closely resembling Guillain–Barré syndrome. This study aims to characterize the clinical presentation, neurophysiological findings, therapeutic strategies, and clinical outcomes ...
A. Llauradó, E. Lainez, H. Ariño, M. Gratacòs‐Viñola, J. L. Seoane, M. Roca‐Herrera, J. L. Restrepo‐Vera, D. Sanchez‐Tejerina, N. Raguer, R. Juntas‐Morales   +9 more
wiley   +1 more source

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial). [PDF]

Aliment Pharmacol Ther
Sanduzzi-Zamparelli M, Matilla A, Lledo JL, Muñoz-Martínez S, Varela M, Iñarrairaegui M, Perelló C, Mínguez B, Llarch N, Márquez L, Guerrero A, Iserte G, Castaño-García A, Carrión L, Fortuny M, Rimola J, García-Criado Á, Domenech G, Torres F, Rios-Guillermo J, Boix L, Samper E, Kateb À, Bruix J, Reig M.   +24 more
europepmc   +1 more source

Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. [PDF]

Curr Oncol Rep
Allen-Tejerina AM, Giannakis P, Ho Lai Yau T, Hillyar CRT, Rallis KS.   +4 more
europepmc   +1 more source

Case Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case. [PDF]

Front Oncol
Okten IN, Baydaş T.
europepmc   +1 more source

Advanced Mucosal Melanoma Therapies: Current Status and Future Directions. [PDF]

Curr Treat Options Oncol
Zhang Y, Zhao D, Wu D.
europepmc   +1 more source

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52. [PDF]

Cancer Sci
Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Goto Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K.   +18 more
europepmc   +1 more source

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma. [PDF]

Cancer Res Commun
Kinget L, McTaggart ES, Demeulenaere O, Roussel E, Boeckx B, Zucman-Rossi J, Couchy G, Vandermeulen H, De Wever L, Baldewijns M, Wozniak A, Joniau S, Lambrechts D, Naulaerts S, Garg AD, Verbiest A, Albersen M, Beuselinck B.   +17 more
europepmc   +1 more source